Seegene Highlights Cutting-Edge '3 Ct' PCR Assay at Medlab Middle East 2023

Seegene, Inc. (Seoul, Korea) is presenting Allplex HPV HR Detection, a PCR assay that applies the company’s leading-edge proprietary '3 Ct' technology, at Medlab Middle East 2023.

In a polymerase chain reaction (PCR), the cycle threshold (Ct) value is used to quantify the concentration of a viral DNA sequence (the target). Due to technological limitations, the conventional real-time PCR technique finds the Ct value of one target in one channel. But Seegene's '3 Ct' technology can provide the Ct value of three targets in one channel without compromising sensitivity and specificity. The successful development is based on Seegene's 20-year expertise and combines 19 different patented technologies, including DPO, TOCE, and MuDT. Using five channels in a single tube, Seegene can provide quantitative data for a total of 15 targets.

The Allplex HPV HR Detection being highlighted at Medlab Middle East 2023 is the world's first commercialized PCR assay applying '3 Ct' technology which has been dubbed the "dream MDx technology." It is designed to detect 14 high-risk human papillomavirus (HPV) types that can cause cervical cancer. It also provides the individual Ct value of each of the types allowing quantitative analysis regarding infection level. Early detection of HPV contributes to the prevention and management of cervical cancer. HPV products from other industry players provide individual Ct values for two high-risk types, HPV 16 and 18. The Allplex HPV HR Detection offers a significant cost advantage compared to existing HPV products and increases accessibility to PCR testing, which had been difficult previously due to high costs. The product is compatible with Seegene's fully automated AIOS (all-in-one system) which is also being highlighted at Medlab Middle East 2023.

Related Links:
Seegene, Inc.